Company shares are trading at $2.28 slightly over $2.10, the stock’s 50 day moving average and well above the 200 day moving average of $1.60. The 50 day moving average was up $0.18 or +8.72% and the 200 day average was up $0.68. Trading was light with 23K shares changing hands by the end of trading on Tuesday. Volume was down 88.93% under the stocks average daily volume.
Traders are feeling more bearish on the company if you put credence in the increase in short interest. The company saw a rise in short interest of 47.54% as of September 29, 2017 from the last reporting period. Short interest grew from 845,353 to 1,247,225 over that period. With short interest at 1,247,225 and short average daily volume at 5,720,838, the short-interest ratio is 0.0 and the percentage of shorted shares was 0.06% on September 29.
The following firms have recently changed their position in CAPR. As of the end of the quarter Sabby Management, LLC had sold a total of 213,389 shares trimming its holdings by 89.8%. The value of the total investment in Capricor Therapeutics, Inc. decreased from $791,000 to $20,000 a change of $771,000 since the last quarter. As of quarter end Kcg Holdings, Inc. had acquired 152,614 shares growing its stake by 571.9%. The value of the company’s investment in Capricor Therapeutics, Inc. went from $90,000 to $149,000 increasing 65.6% quarter over quarter.
Granite Point Capital Management, L.p. reduced its stake by shedding 24,300 shares a decrease of 41.9%. Granite Point Capital Management, L.p. controls 33,750 shares worth $28,000. The total value of its holdings decreased 85.5%. As of the end of the quarter Llbh Private Wealth Management, LLC had acquired a total of 40,000 shares growing its position 27.7%. The value of the investment in CAPR went from $489,000 to $153,000 a change of 68.7% quarter to quarter.
In the latest earnings report the EPS was $-0.82 and is projected to be $-0.70 for the current year with 23,496,000 shares outstanding. Next quarter’s EPS is estimated at $-0.19 and the next full year EPS is projected to be $-0.76.
Capricor Therapeutics, Inc., launched on January 26, 2007, is a clinical-stage biotechnology company focused on the discovery, development and commercialization of therapeutics. The Company focuses on discovering, developing and commercializing regenerative medicine and large molecule products for the treatment of disease, with a primary focus on the treatment of cardiovascular diseases, including orphan indications. The Company has over four clinical trials aiming to treat cardiovascular diseases in various progressions of the disease state. The Business’s core technology is based on cardiospheres (CSps), which are multi-cell clusters of cardiac-derived cells. The Business’s lead product candidate, the Cardiosphere-Derived Cells (CDCs), are the single cell monolayer product of the CSps. CDCs are small enough that within acceptable dose limits, they can be injected down a coronary artery without damaging the heart muscle. Both CSps and CDCs are derived from a deceased human donor (allogeneic source) or from heart tissue taken directly from recipient patients themselves (autologous source)..